- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT06803771
Vigilancia de la salud pancreática después del diagnóstico de diabetes (SAFE-D)
An Interventional Study to Evaluate the cfDNA Pancreatic Cancer Test (Avantect) in the Early Detection of Pancreatic Cancer in Participants With Newly Diagnosed Diabetes Mellitus or Newly Elevated HbA1c
The goal of this interventional study is to evaluate if the novel diagnostic blood test, called Avantect can early detect pancreatic cancer in patients diagnosed with type 2 diabetes or with elevated sugar levels within the last 200 days.
Participants will:
- attend 3 study visits over 12 months time
- provide a blood sample at each study visit
- complete an anxiety questionnaire at each visit.
Descripción general del estudio
Estado
Condiciones
Intervención / Tratamiento
Descripción detallada
Pancreatic cancer (PC) is one of the most lethal common cancers (five-year survival 5-7%). In more than 80% of patients the disease has spread before it is detected, ruling out potentially curative treatment options. Early detection offers the possibility of surgery leading to significantly improved overall survival.
There is currently no accepted screening test for pancreatic cancer. The Aventect test is designed to detect clues, or biomarkers for the presence or absence of pancreatic cancer signals in blood. The SAFE-D study will evaluate if the Avantect test can detect pancreatic cancer at an earlier more treatable stage.
People older than 50 years who have recently been diagnosed with type II diabetes have up to ten times higher-than-average risk of having pancreatic cancer without knowing.
The study will recruit 5,000 participants aged 50-84 years old diagnosed with type II diabetes or elevated Hb1Ac levels within the last 200 days from GP practices over 3 years.
Participants will have their blood samples analysed on the Avantect test as soon as possible. If a pancreatic biomarker is detected the participants will be informed and offered a standard of care diagnostic imaging scan (MRI or CT) to rule out pancreatic cancer. All participants will be followed remotely via cancer and mortality registry searches for 3 years from consent to assess any cancer diagnosed during this time.
Tipo de estudio
Inscripción (Estimado)
Fase
- No aplica
Contactos y Ubicaciones
Estudio Contacto
- Nombre: SAFE-D Trial Manager
- Número de teléfono: +442381205154
- Correo electrónico: safed@soton.ac.uk
Ubicaciones de estudio
-
-
-
Ashton-under-Lyne, Reino Unido, OL6 6HD
- Activo, no reclutando
- Ashton Medical Group
-
Birmingham, Reino Unido, B14 4DU
- Reclutamiento
- Yardley Wood Health Centre
-
Contacto:
- Anson-Wisniewska
- Número de teléfono: 02380215154
- Correo electrónico: safed@soton.ac.uk
-
Bournemouth, Reino Unido, BH7 7DW
- Activo, no reclutando
- Bournemouth Research Hub
-
Bromborough, Reino Unido, CH62 6EE
- Reclutamiento
- Eastham Group Practice
-
Contacto:
- Anson-Wisniewska
- Número de teléfono: 02380215154
- Correo electrónico: safed@soton.ac.uk
-
London, Reino Unido, NW10 2PT
- Reclutamiento
- Willesden Medical Centre
-
Contacto:
- Anson-Wisniewska
- Número de teléfono: 02380215154
- Correo electrónico: safed@soton.ac.uk
-
London, Reino Unido, SW1P 2PF
- Reclutamiento
- South Westminster Centre
-
Contacto:
- Anson-Wisniewska
- Número de teléfono: 02380215154
- Correo electrónico: safed@soton.ac.uk
-
London, Reino Unido, W7 1DR
- Reclutamiento
- The Cuckoo Lane Practice
-
Contacto:
- Anson-Wisniewska
- Número de teléfono: 02380215154
- Correo electrónico: safed@soton.ac.uk
-
Manchester, Reino Unido, M14 6WP
- Activo, no reclutando
- Bodey Medical Centre
-
Manchester, Reino Unido, M23 1JX
- Activo, no reclutando
- Bowland Medical Practice
-
Manchester, Reino Unido, M23 2SY
- Activo, no reclutando
- The Maples Medical Centre
-
Nottingham, Reino Unido, NG17 4JL
- Reclutamiento
- King's Mill Hospital (Sherwood Forest) Research Van
-
Contacto:
- Anson-Wisniewska
- Número de teléfono: 02380215154
- Correo electrónico: safed@soton.ac.uk
-
Portsmouth, Reino Unido, PO1 3HN
- Activo, no reclutando
- Portsmouth Research Hub
-
Rossendale, Reino Unido, BB4 5SL
- Reclutamiento
- Hazelvalley Family Practice
-
Contacto:
- Anson-Wisniewska
- Número de teléfono: 02380215154
- Correo electrónico: safed@soton.ac.uk
-
Ruislip, Reino Unido, HA4 8NX
- Reclutamiento
- Pembroke Centre (Hillingdon)
-
Contacto:
- Anson-Wisniewska
- Número de teléfono: 02380215154
- Correo electrónico: safed@soton.ac.uk
-
Southampton, Reino Unido, SO30 3JB
- Reclutamiento
- Moorgreen Hospital
-
Contacto:
- Anson-Wisniewska
- Número de teléfono: 02380215154
- Correo electrónico: safed@soton.ac.uk
-
Southampton, Reino Unido, SO15 33UA
- Activo, no reclutando
- Southampton Research Hub (Shirley Research Hub)
-
Uttoxeter, Reino Unido, ST14 8JG
- Reclutamiento
- Balance Street Health Centre
-
Contacto:
- Anson-Wisniewska
- Número de teléfono: 02380215154
- Correo electrónico: safed@soton.ac.uk
-
Uxbridge, Reino Unido, UB8 1UW
- Reclutamiento
- Civic Centre
-
Contacto:
- Anson-Wisniewska
- Número de teléfono: 02380215154
- Correo electrónico: safed@soton.ac.uk
-
Walsall, Reino Unido, WS6 6EW
- Reclutamiento
- Quinton Practice
-
Contacto:
- Anson-Wisniewska
- Número de teléfono: 02380215154
- Correo electrónico: safed@soton.ac.uk
-
Weymouth, Reino Unido, DT4 0QE
- Activo, no reclutando
- Weymouth Research Hub
-
-
Cheshire
-
Sandbach, Cheshire, Reino Unido, CW11 1EQ
- Activo, no reclutando
- Ashfields Primary Care Centre
-
-
Kent
-
Maidstone, Kent, Reino Unido, ME16 9QQ
- Reclutamiento
- Maidstone and Tunbridge Wells NHS Trust
-
Contacto:
- Anson-Wisniewska
- Número de teléfono: 02380215154
- Correo electrónico: safed@soton.ac.uk
-
-
Leicester Forest East
-
Leicester, Leicester Forest East, Reino Unido, LE3 3LW
- Reclutamiento
- Forest Medical Group
-
Contacto:
- Anson-Wisniewska
- Número de teléfono: 02380215154
- Correo electrónico: safed@soton.ac.uk
-
-
Leicestershire
-
Kibworth Beauchamp, Leicestershire, Reino Unido, LE8 0LG
- Reclutamiento
- South Leicestershire Medical Group
-
Contacto:
- Anson-Wisniewska
- Número de teléfono: 02380215154
- Correo electrónico: safed@soton.ac.uk
-
-
Staffordshire
-
Burton-on-Trent, Staffordshire, Reino Unido, DE14 3RH
- Reclutamiento
- Peel Croft Surgery
-
Contacto:
- Anson-Wisniewska
- Número de teléfono: 02380215154
- Correo electrónico: safed@soton.ac.uk
-
Kingswinford, Staffordshire, Reino Unido, DY6 8DN
- Reclutamiento
- Kingswinford Medical Practice
-
Contacto:
- Anson-Wisniewska
- Número de teléfono: 02380215154
- Correo electrónico: safed@soton.ac.uk
-
Leek, Staffordshire, Reino Unido, ST13 6QR
- Reclutamiento
- Park Medical Centre
-
Contacto:
- Anson-Wisniewska
- Número de teléfono: 02380215154
- Correo electrónico: safed@soton.ac.uk
-
Stratford-upon-Avon, Staffordshire, Reino Unido, CV37 6HJ
- Reclutamiento
- Trinity Court Surgery
-
Contacto:
- Anson-Wisniewska
- Número de teléfono: 02380215154
- Correo electrónico: safed@soton.ac.uk
-
-
Surrey
-
Brockham, Surrey, Reino Unido, RH3 7NJ
- Reclutamiento
- Brockwood Medical Practice
-
Contacto:
- Anson-Wisniewska
- Número de teléfono: 02380215154
- Correo electrónico: safed@soton.ac.uk
-
Epsom, Surrey, Reino Unido, KT17 4BL
- Reclutamiento
- Integrated Care Partnership/ The Old Cottage Hospital
-
Contacto:
- Anson-Wisniewska
- Número de teléfono: 02380215154
- Correo electrónico: safed@soton.ac.uk
-
Warlingham, Surrey, Reino Unido, CR6 9NW
- Reclutamiento
- Warlingham Green Medical Practice
-
Contacto:
- Anson-Wisniewska
- Número de teléfono: 02380215154
- Correo electrónico: safed@soton.ac.uk
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
- 50 - 84 years of age at the time of enrolment (within year of birth, not month of birth)
- Confirmed type 2 DM diagnosis established within the last 200 days or an initial elevated HbA1c ≥ 48 mmol/mol or 6.5% obtained within the last 200 days. This includes people who have a first elevated HbA1c (≥ 48 mmol/mol or 6.5%) within the last 200 days, even if subsequent HbAc1 measurements return to the the normal range.
- Willing to provide up to 30 mL of blood for each study visit
- Willing and eligible to undergo MRI or CT scan
- Understands the study process and is willing to take part in the study and sign the informed consent form
Exclusion Criteria:
- Prior type I or type II DM diagnosis or an initial HbA1c ≥ 48 mmol/mol or 6.5% obtained prior to the 200-day inclusion window, except gestational elevated HbA1c.
- A history of pancreatic cancer, pancreatic neuroendocrine tumour (pNET) or Pancreatitis
- Under investigation for or confirmed pancreatic cancer
- Under investigation/surveillance for pancreatic cyst
- Any known pancreatic surgery (not including ERCP), or other major surgery requiring anaesthesia within 3 months
- Any invasive solid or haematological cancer in the past 3 years, including cancer recurrence after treatment in the last 3 years
- BMI > 40 at the time of consent
- Blood transfusion within 1 month
- Solid organ transplant recipient
- Currently pregnant
- Needing dialysis
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Diagnóstico
- Asignación: N / A
- Modelo Intervencionista: Asignación de un solo grupo
- Enmascaramiento: Ninguno (etiqueta abierta)
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Experimental: Interventional
Participants will have their blood samples tested on the Avantect test within prioritised timeframe. The "detected" Avantect test results will be shared with the participants and their General Practitioners (GPs) to allow for further MRI or CT investigations by the local clinical team. |
Avantect test |
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Sensitivity of the Avantect test
Periodo de tiempo: The final analysis will be carried out after 3-year follow up data has been collected for all 5,000 participants.
|
The proportion of individuals with one or more Avantect "detected" test result who have pancreatic cancer diagnosed via imaging in relation to all individuals in the study who had pancreatic cancer diagnosed. |
The final analysis will be carried out after 3-year follow up data has been collected for all 5,000 participants.
|
|
Specificity of the Avantect test
Periodo de tiempo: The final analysis will be carried out after 3-year follow-up data has been collected for all 5,000 participants.
|
The proportion of individuals with one or more Avantect "not detected" test results, and no Avantect "detected" results, who did not have a pancreatic cancer diagnosis in relation to all individuals in the study who did not have a pancreatic cancer diagnosis. |
The final analysis will be carried out after 3-year follow-up data has been collected for all 5,000 participants.
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Stage shift
Periodo de tiempo: The analysis will be carried out after 3-year follow-up data has been collected for all 5,000 participants.
|
The proportion of pancreatic cancers cases diagnosed at stage I/II out of all participants diagnosed with pancreatic cancer between SAFE-D participants and point-estimate of the proportion from comparative data. Stage shift will be considered successful if the lower-bound of the 95% one-sided proportion in SAFE-D participants is higher than the proportion from comparative data. |
The analysis will be carried out after 3-year follow-up data has been collected for all 5,000 participants.
|
|
Positive Predictive Value (PPV) of Avantect test in detecting pancreatic cancer (PC)
Periodo de tiempo: The final analysis will be carried out after 3-year follow-up data has been collected for all 5,000 participants.
|
Percentage of participants with an Avantect "detected" result who have pancreatic cancer diagnosed. The analysis will be conducted with a sample size of 5,000, pancreatic cancer prevalence of 0.8%, and 5% lost from the per protocol population. There will be an expected 261 individuals with an Avantect "detected" result. 9.6% (25/261) are expected to have a PC. PPV will be considered successful if a null PPV of 5% can be ruled out at a one-sided p-value of 0.05. |
The final analysis will be carried out after 3-year follow-up data has been collected for all 5,000 participants.
|
|
Negative Predictive Value (NPV) of Avantect test in ruling out pancreatic cancer (PC)
Periodo de tiempo: The analysis will be carried out after 3-year follow-up data has been collected for all 5,000 participants.
|
With a sample size of 5,000, PC prevalence of 0.8%, and 5% lost from the per protocol population, there will be an expected 4,489 individuals without an Avantect "detected" result. 99.6% (4,476/4,489) are expected to not have a diagnosis of PC. NPV will be considered successful if a null NPV of 99% can be ruled out at a one-sided p-value of 0.05. |
The analysis will be carried out after 3-year follow-up data has been collected for all 5,000 participants.
|
|
Resection rate of pancreatic cancer
Periodo de tiempo: The analysis will be carried out after 3-year follow-up data has been collected for all 5,000 participants.
|
Percentage of participants with pancreatic cancer who underwent resection. The analysis will be conducted by comparing the proportion of pancreati cancer cases that underwent resection as a treatment modality between SAFE-D participants and the point-estimate of the proportion from comparative data. Resection rate will be considered successful if the lower-bound of the 95% one-sided proportion in SAFE-D participants is higher than the proportion from comparative data. |
The analysis will be carried out after 3-year follow-up data has been collected for all 5,000 participants.
|
|
Resectability
Periodo de tiempo: The analysis will be carried out after 3-year follow-up data has been collected for all 5,000 participants.
|
Percentage of pancreatic cancers deemed resectable by the study MDST. |
The analysis will be carried out after 3-year follow-up data has been collected for all 5,000 participants.
|
Otras medidas de resultado
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Time-to-event outcomes
Periodo de tiempo: The analysis will be carried out after 3-year follow-up data has been collected for all 5,000 participants.
|
To estimate the time from new onset diabetes diagnosis to pancreatic cancer diagnosis. |
The analysis will be carried out after 3-year follow-up data has been collected for all 5,000 participants.
|
|
Overall survival
Periodo de tiempo: The analysis will be carried out after 3-year follow-up data has been collected for all 5,000 participants.
|
To estimate the overall survival of study participants. |
The analysis will be carried out after 3-year follow-up data has been collected for all 5,000 participants.
|
|
Effect of the Avantect test on state anxiety over time
Periodo de tiempo: The analysis will be carried out after 3-year follow-up data has been collected for all 5,000 participants.
|
To assess the effect of the Avantect test on state anxiety over time. |
The analysis will be carried out after 3-year follow-up data has been collected for all 5,000 participants.
|
|
High-grade neoplasia
Periodo de tiempo: The analysis will be carried out after 3-year follow-up data has been collected for all 5,000 participants.
|
To investigate the performance characteristics for high-grade neoplasia. |
The analysis will be carried out after 3-year follow-up data has been collected for all 5,000 participants.
|
Colaboradores e Investigadores
Patrocinador
Colaboradores
Publicaciones y enlaces útiles
Enlaces Útiles
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Finalización primaria (Estimado)
Finalización del estudio (Estimado)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
- Enfermedades del sistema endocrino
- Neoplasias por sitio
- Neoplasias
- Enfermedades metabólicas
- Neoplasias del Sistema Digestivo
- Enfermedades del Sistema Digestivo
- Trastornos del metabolismo de la glucosa
- Neoplasias de glándulas endocrinas
- Enfermedades pancreáticas
- Enfermedades Nutricionales y Metabólicas
- Diabetes Mellitus, Tipo 2
- Neoplasias pancreáticas
- Diabetes mellitus
- Cáncer de páncreas, adulto
Otros números de identificación del estudio
- RHMGSU0292
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
producto fabricado y exportado desde los EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .